| Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality (NCT05095155) | Asfendiyarov Kazakh National Medical University | 2022-04-01 |
| Induced-T Cell Like NK Cells for B Cell Malignancies (NCT04747093) | Nanfang Hospital, Southern Medical University | 2021-01-29 |
| Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT (NCT04516551) | Xinqiao Hospital of Chongqing | 2020-11-20 |
| CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies (NCT04605666) | Nanfang Hospital, Southern Medical University | 2020-05-01 |
| CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (NCT04260945) | Hebei Yanda Ludaopei Hospital | 2020-03-10 |
| Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies (NCT03881774) | Henan Cancer Hospital | 2019-02-27 |
| CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies (NCT04156178) | iCell Gene Therapeutics | 2018-08-01 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies (NCT04156243) | iCell Gene Therapeutics | 2018-02-01 |
| A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma (NCT03398967) | Chinese PLA General Hospital | 2018-01-02 |
| Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies (NCT03098355) | Zhujiang Hospital | 2017-12-30 |
| Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (NCT03302403) | Kang YU | 2017-12-29 |
| A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia (NCT03463928) | Chinese PLA General Hospital | 2017-10-08 |
| A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma (NCT03166878) | Chinese PLA General Hospital | 2017-06-01 |
| A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia (NCT03383952) | Immune Cell, Inc. | 2017-03-01 |
| CAR T Cells for Refractory B Cell Malignancy (NCT02963038) | Hebei Senlang Biotechnology Inc., Ltd. | 2016-06-01 |
| CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. (NCT02132624) | Uppsala University | 2014-04-01 |
| A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia (NCT01683279) | Seattle Children's Hospital | 2012-03-25 |
| Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (NCT01626495) | University of Pennsylvania | 2011-08-17 |
| Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (NCT00849654) | Pharmacyclics LLC. | 2009-02-01 |
| Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia (NCT00230282) | Steven E. Coutre | 2004-07-01 |